In August 2026, Charles River Laboratories International reported second-quarter revenue of US$1,004.08 million, swinging to a small net loss, and simultaneously cut its 2026 GAAP EPS guidance to US$3.05–US$3.35 per share, largely due to losses tied to recent divestitures. Despite these GAAP headwinds, the company exceeded non-GAAP earnings expectations, raised its full-year adjusted EPS outlook, and highlighted strong momentum in its Discovery and Safety Assessment segment, pointing to...
stock
Be The Investor Research
Read Original Source (Finance)
Charles River (CRL) Is Up 11.0% After Raising Adjusted EPS Outlook Amid Divestiture-Driven GAAP Losses – Has The Bull Case Changed?
In August 2026, Charles River Laboratories International reported second-quarter revenue of US$1,004.08 million, swinging to a small net loss, and simultaneously cut its 2026 GAAP EPS guidance to US$3.05–US$3.35 per share, largely due to losses tied to recent divestitures. Despite these GAAP headwinds, the company exce